SCHEMBL3835618

SCHEMBL3835618

COc1cc(O)c(C(N)=O)cc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
HPGD P15428 2/20 0.57
HSD17B10 Q99714 2/20 0.57
LMNA P02545 1/20 0.57
CYP3A4 P08684 1/20 0.57
MAPT P10636 1/20 0.57
RECQL P46063 1/20 0.57
HTT P42858 2/20 0.55
HMGCR P04035 1/20 0.50
RAB9A P51151 2/20 0.44
SLC22A6 Q4U2R8 1/20 0.44
SLC22A8 Q8TCC7 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
MKNK2 Q9HBH9 1/20 0.43
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28576535 0.90 HTT (0.68) KDM4EHPGDHSD17B10LMNACYP3A4
SCHEMBL30210988 0.83 LCK (0.53) KDM4EHPGDHSD17B10LMNACYP3A4
SCHEMBL15074289 0.83 HTT (0.50) KDM4EHPGDHSD17B10LMNACYP3A4
SCHEMBL3836141 0.82 MAPT (0.64) KDM4EHPGDHSD17B10LMNACYP3A4
SCHEMBL14780513 0.82 HTT (0.81) KDM4EHPGDHSD17B10LMNACYP3A4
SCHEMBL31175997 0.82 HTT (0.81) KDM4EHPGDHSD17B10LMNACYP3A4
SCHEMBL3461530 0.80 KDM4E (0.57) KDM4EHPGDHSD17B10LMNACYP3A4
SCHEMBL23511720 0.80 ALDH1A1 (0.52) KDM4EHPGDHSD17B10CYP3A4MAPT
Water SCHEMBL28292285 0.78 ALDH1A1 (0.50) KDM4EHPGDHSD17B10CYP3A4MAPT
SCHEMBL69624 0.78 MAOB (0.59) KDM4EHPGDHSD17B10LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0526302-B1 Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica OREAL (FR) 1995-03-01 EP claimed
EP-0526302-A1 Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica L'OREAL (FR) 1993-02-03 EP claimed
US-8505730-B2 Compositions, kits and regimens for the treatment of skin, especially décolletage JR CHEM, LLC (US) 2013-08-13 US disclosed
US-20120312717-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE JR CHEM, LLC (US) 2012-12-13 US disclosed
US-8273791-B2 Compositions, kits and regimens for the treatment of skin, especially décolletage JR CHEM, LLC (US) 2012-09-25 US disclosed
EP-2087880-A2 Compositions, kits and regimens for the treatment of skin, especially décolletage Jr Chem, LLC (US) 2009-08-12 EP disclosed
US-20090176876-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE JR CHEM, LLC (US) 2009-07-09 US disclosed
US-6960347-B2 Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives L'OREAL (FR) 2005-11-01 US disclosed
US-20010036446-A1 Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives L'OREAL (FR) 2001-11-01 US disclosed
EP-0526302-B1 Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica OREAL (FR) 1995-03-01 EP disclosed
EP-0526302-A1 Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica L'OREAL (FR) 1993-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176876-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE RARG, RARA, RXRG KDM4E 3387/4885HPGD 92/4885HSD17B10 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.